WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1993021232) IMMUNOTOXINS DIRECTED AGAINST c-erbB-2 (HER-2/$i(neu)) RELATED SURFACE ANTIGENS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1993/021232    International Application No.:    PCT/US1993/003292
Publication Date: 28.10.1993 International Filing Date: 08.04.1993
Chapter 2 Demand Filed:    25.10.1993    
IPC:
A61K 47/48 (2006.01)
Applicants: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US)
Inventors: ROSENBLUM, Michael, G.; (US).
SHAWVER, Laura, K.; (US)
Agent: WEILER, James, F.; 1 Riverway, Suite 1560, Houston, TX 77056 (US)
Priority Data:
07/867,728 10.04.1992 US
Title (EN) IMMUNOTOXINS DIRECTED AGAINST c-erbB-2 (HER-2/$i(neu)) RELATED SURFACE ANTIGENS
(FR) IMMUNOTOXINES DIRIGEES CONTRE DES ANTIGENES DE SURFACE APPARENTEES A c-erbB-2(HER-2/$i(neu))
Abstract: front page image
(EN)Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.
(FR)L'invention décrit de nouvelles immunotoxines, ainsi que des procédés de traitement de maladies néoplasiques. Elle décrit plus particulièrement des immunotoxines comprenant la conjugaison d'une fraction de ciblage de c-erbB-2 et d'un modulateur de croissance cellulaire. Ces immunotoxines détruisent, de façon spécifique et sélective, des cellules cancéreuses surexprimant la protéine de c-erbB-2. Ces nouvelles immunotoxines présenteraient une efficacité dans le traitement de carcinomes mammaires, ovariens ou pulmonaires chez l'homme, de tumeurs gastriques, d'adénocarcinomes de la glande salivaire et du colon.
Designated States: AU, CA, FI, JP, KR, KZ, NO, NZ, RU.
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)